NCT03319810View on ClinicalTrials.gov

Effect of IVIG on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

January 4, 2018

Primary Completion Date

July 19, 2018

Study Completion Date

July 19, 2018

Conditions
Mild Cognitive Impairment
Interventions
BIOLOGICAL

Octagam 10%

FDA approved human normal immunoglobulin solution ready for intravenous administration

Trial Locations (1)

95816

Sutter Neuroscience Medical Group, Sacramento

All Listed Sponsors
lead

Sutter Health

OTHER

NCT03319810 - Effect of IVIG on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer Disease | Biotech Hunter | Biotech Hunter